| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Johnson & Johnson (JNJ) has 22 insiders with recent SEC Form 4 filings, including 1 buy and 10 sells. JNJ is classified in the Pharmaceuticals industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 4.04M | $932.11M | - | |
| VP | 193.5K | $44.65M | - | |
| VP | 46.2K | $10.66M | - | |
| VP | 34.7K | $8.00M | - | |
| CEO | 30.9K | $7.12M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Oct 21, 2016 | Prince Charles | Director | Buy | 875 | $114.11 | $99,846.25 | +3.4% | |
| Jul 26, 2016 | Caruso Dominic J | Exec VP, Finance; CFO | Sale+OE | 41,146 | $125.01 | $5,143,809.59 | -26.1% | |
| Jul 22, 2016 | Kapusta Ronald A | Controller, CAO | Sale+OE | 2,935 | $125.01 | $366,895.55 | -10.2% | |
| Jun 7, 2016 | Pruden Gary J | Exec VP, Ww Chair, Med Devices | Sell | 9,735 | $116.03 | $1,129,552.05 | -18.2% | |
| Jun 7, 2016 | Kapusta Ronald A | Controller, CAO | Sale+OE | 3,000 | $115.79 | $347,381.10 | -10.4% | |
| May 10, 2016 | Kapusta Ronald A | Controller, CAO | Sale+OE | 3,957 | $114.77 | $454,156.76 | -13.3% | |
| Feb 17, 2016 | Stoffels Paulus | Chief Scientific Officer | Sale+OE | 125,000 | $102.43 | $12,803,250.00 | -50.5% | |
| Feb 3, 2016 | Fasolo Peter61 | VP, Global Human Resources | Sale+OE | 151,385 | $104.12 | $15,762,008.51 | -66.7% | |
| Nov 20, 2015 | Ullmann Michael H | VP, General Counsel | Sale+OE | 17,650 | $102.47 | $1,808,542.55 | -18.6% | |
| Nov 2, 2015 | Caruso Dominic J | VP, Finance; CFO | Sale+OE | 20,569 | $102.21 | $2,102,423.31 | -18.8% |